Journal articles: 'Harts Range (N T )'

1

Bell, Steve, Elspeth Pennington, James Hill, and Joanna Harrison. "Prehospital airway management." Journal of Paramedic Practice 14, no. 2 (February 2, 2022): 51–53. http://dx.doi.org/10.12968/jpar.2022.14.2.51.

Full text

Abstract:

The prehospital emergency airway management is a key moderating factor for patient survival and mortality rates. There has been much debate around the optimum method of prehospital emergency airway management. This commentary critically appraises a recent systematic review which assesses the harms and benefits of three different airway management strategies for a range of emergency clinical scenarios. Commentary on: Carney N, Totten AM, Cheney T et al. Prehospital Airway Management: A Systematic Review. Prehosp Emerg Care. 2021;1–12. https://doi.org/10.1080/10903127.2021.1940400

APA, Harvard, Vancouver, ISO, and other styles

2

Miller, Peter, Amy Pennay, Rebecca Jenkinson, Nicolas Droste, Tanya Chikritzhs, Stephen Tomsen, Phillip Wadds, et al. "Patron offending and intoxication in night-time entertainment districts (POINTED): A study protocol." International Journal of Alcohol and Drug Research 2, no. 1 (March 8, 2013): 69–76. http://dx.doi.org/10.7895/ijadr.v2i1.74.

Full text

Abstract:

Miller, P., Pennay, A., Jenkinson, R., Droste, N., Chikritzhs, T., Tomsen, S., Wadds, P., Jones, S. C., Palmer, D., Barrie, L. & Lubman, D. I. (2013). Patron offending and intoxication in night-time entertainment districts (POINTED): A study protocol. International Journal of Alcohol and Drug Research, 2(1), 69-76. doi: 10.7895/ijadr.v2i1.74 (http://dx.doi.org/10.7895/ijadr.v2i1.74)Risky alcohol consumption is the subject of considerable community concern in Australia and internationally, particularly the risky drinking practices of young people consuming alcohol in the night-time economy. This study will determine some of the factors and correlates associated with alcohol-related risk-taking, offending and harm in and around licensed venues and night-time entertainment precincts across five Australian cities (three metropolitan and two regional). The primary aim of the study is to measure levels of pre-drinking, drinking in venues, intoxication, illicit drug use and potentially harmful drinking practices (such as mixing with energy drinks) of patrons in entertainment areas, and relating this to offending, risky behaviour and harms experienced. The study will also investigate the effects of license type, trading hours, duration of drinking episodes and geographical location on intoxication, offending, risk-taking and experience of harm. Data collection involves patron interviews (incorporating breathalysing and drug testing) with 7500 people attending licensed venues. Intensive venue observations (n=112) will also be undertaken in a range of venues, including pubs, bars and nightclubs. The information gathered through this study will inform prevention and enforcement approaches of policy makers, police and venue staff.

APA, Harvard, Vancouver, ISO, and other styles

3

Stallings, Sarah C., Jennifer Cunningham-Erves, Carleigh Frazier, Jabári S. Ichimura, Thelma C. Hurd, Jordan Jurinsky, Amber Acquaye, Jacquelyn S. Dalton, and Consuelo H. Wilkins. "Development and Validation of the Perceptions of Research Trustworthiness Scale to Measure Trust Among Minoritized Racial and Ethnic Groups in Biomedical Research in the US." JAMA Network Open 5, no. 12 (December 29, 2022): e2248812. http://dx.doi.org/10.1001/jamanetworkopen.2022.48812.

Full text

Abstract:

ImportanceHistorically, trust in biomedical research has been lower among minoritized racial and ethnic groups who are underrepresented in and excluded from research, with the same groups experiencing worse health outcomes. Unfortunately, instruments that measure trust may not capture components of trust relevant to minoritized racial and ethnic groups.ObjectiveTo develop and validate a scale to measure trust in biomedical research among minoritized racial and ethnic groups.Design, Setting, and ParticipantsThis cross-sectional, community-based survey study compared trust and distrust in biomedical research among Black, Latino, and White subgroups in the US using the Perceptions of Research Trustworthiness (PoRT) scale. The scale was developed between March 22, 2016, and September 19, 2018, as part of this study, and its structure, reliability, and validity were examined during pilot (n = 381) and validation (n = 532) phases between February 4, 2019, and July 27, 2021. Convenience samples of adult participants (aged ≥18 years) were recruited locally (Nashville, Tennessee, and San Antonio, Texas) and nationally through the ResearchMatch and Cint online platforms.Main Outcomes and MeasuresOverall and individual item Trust and Distrust subscale scores were compared. Overall Trust and Distrust scores were compared by race and ethnicity using a Kruskal-Wallis H test and individual item scores were compared using independent samples t test.ResultsOf the 532 participants in the scale validation study, 144 (27.1%) were Black, 90 (16.9%) were Latino, and 282 (53.0%) were White. Participants had a median age of 43 years (range, 18-90 years), 352 (66.2%) were women, and 198 (37.2%) had educational attainment levels less than a college degree. Factor analysis of the 18-item PoRT scale revealed a 2-factor structure with two 9-item PoRT subscales (Trust and Distrust), which demonstrated high internal consistency (Cronbach α = 0.72 and 0.87, respectively). Mean (SD) Trust subscale scores were lower among Black (34.33 [2.02]) and Latino (34.55 [1.97]) participants compared with White participants (36.32 [1.81]; P &lt; .001). Mean (SD) Distrust subscale scores were higher among Black (21.0 [2.15]) and Latino (20.53 [2.21]) participants compared with White participants (18.4 [2.03]; P &lt; .001). Individual item results showed that Black and Latino participants were less trusting and more distrusting than White individuals on items related to risks, harms, secrecy, confidentiality, and privacy.Conclusions and RelevanceThese findings suggest that the PoRT scale incorporates trust and trustworthiness concepts relevant among Black and Latino individuals and may allow more precise assessment of trust in research among these groups.

APA, Harvard, Vancouver, ISO, and other styles

4

Pietraß, Tanja, Paul K. Burkert, and Hans H. Karsch. "7Li-Solid-State-NMR of [Li(N,N,N',N'-Tetramethylethylenediamine)] CLO4 and [Li (N,N,N', N'-Tetramethylethylenediamine)2] Al(CH3)4." Zeitschrift für Naturforschung A 47, no. 1-2 (February 1, 1992): 117–19. http://dx.doi.org/10.1515/zna-1992-1-220.

Full text

Abstract:

Abstract The temperature dependent 7Li-solid-state-NMR spectra of the two compounds [Li(N,N,N',N'- tetramethylethylenediamine)]ClO4 and [Li(N,N,N\N tetramethylethylenediamine)2]Al(CH3)4 are presented. Both compounds were investigated in the temperature range 160 K ≦ T ≦ 360 K. Above room temperature, the spectra for the tetramethylaluminate show the typical line shape for a first-order quadrupolar-disturbed central transition with an axially symmetric asymmetry parameter and a slightly positive temperature dependence of the quadrupole coupling constant. The mean temperature coefficient ά = + 9 • 10-4 K -1 . The quadrupole coupling constant is in the range of 36-39 kHz. In the Temperature range 240 K ≦ T ≦ 275 K the quadrupolar splitting cannot be resolved. Below 240 K the quadrupole coupling constant is about 100 kHz. Contrarily, in the Perchlorate the quadrupole coupling constant is 75 kHz and is temperature independent. With increasing temperature the satellites lower in intensity and the central transition undergoes motional narrowing

APA, Harvard, Vancouver, ISO, and other styles

5

Weber, G., C. Cougnard, M. H. Simonot-Grange, J. P. Bellat, and O. Bertrand. "t-Curves for n-Hexane." Adsorption Science & Technology 9, no. 4 (December 1992): 258–68. http://dx.doi.org/10.1177/026361749200900404.

Full text

Abstract:

The adsorption and desorption isotherms of n-hexane on powdered alumina and silica have been studied at 25°C over a wide range of relative pressures. Two t-curves for pore structure analysis are proposed, one for alumina (C = 12) and the second for silica (3 ≤ C ≤ 9). The statistical thickness t of the adsorbed n-hexane layer has been drawn as a function of the relative pressure assuming a maximal thickness of 0.55 nm and a mean thickness of 0.42 nm for the monolayer. The results are discussed in relation to previous published data.

APA, Harvard, Vancouver, ISO, and other styles

6

Maris, Thierry. "N,N,N-Tributylbutan-1-aminium (T-4)-(cyano-κC)trihydroborate." Acta Crystallographica Section E Structure Reports Online 69, no. 11 (October 26, 2013): o1713. http://dx.doi.org/10.1107/s1600536813028924.

Full text

Abstract:

In the crystal structure of the title salt, C16H36N+·CH3BN−, the tetra-n-butylammonium cations and [BH3(CN)]−anions are connectedviaweak C—H...N interactions, forming chains along theb-axis direction. The anion is almost linear with an N—C—B angle of 178.7 (2)°. The C—N—C angle values at the core of the tetra-n-butylammonium cation range from 105.74 (11) to 111.35 (11)° with an average of 109.49 (11)°, close to the ideal tetrahedral value.

APA, Harvard, Vancouver, ISO, and other styles

7

Herranz, Daniel, Alberto Ambesi-Impiombato, Teresa Palomero, Stephanie A. Schnell, Laura Belver, Agnieszka A. Wendorff, Luyao Xu, et al. "N-Me, a Long Range T-Cell Specific Oncogenic Enhancer in T-ALL." Blood 124, no. 21 (December 6, 2014): 487. http://dx.doi.org/10.1182/blood.v124.21.487.487.

Full text

Abstract:

Abstract Over the last years, numerous studies have dissected the mutational landscape of T-cell acute lymphoblastic leukemia (T-ALL) resulting in the identification of numerous oncogenes and tumor suppressors implicated in T-cell transformation. However, most genetic abnormalities found in cancer are located in intergenic regions, whose role in cancer development, if any, remains poorly understood. Here we hypothesized that recurrent cancer-associated intergenic mutations, amplifications and deletions may implicate strong transcriptional regulatory sequences responsible for the activation of key oncogenic factors in the pathogenesis of T-ALL. To address this question, we first used ChIPseq analysis to map the genomic landscape of enhancer sequences controlled by NOTCH1, a critical T-ALL oncogene activated by mutations in over 60% of human T-ALLs. In addition, we performed high resolution aCGH analysis of somatic chromosomal amplifications and deletions in a comprehensive series of 160 T-ALL samples. These analyses revealed recurrent focal duplications at chromosome 8q24 in 8/160 (5%) T-ALL cases in an area devoid of protein-coding genes containing a prominent 1 kb NOTCH1-binding peak. Strikingly, this putative oncogenic element is located +1,427 kb 3’ from the MYC locus and chromatin configuration 3C analysis demonstrated its direct association with the MYC proximal promoter. Multispecies DNA sequence alignment revealed remarkable conservation of this region in mammals, birds and reptiles and local ChIP analysis revealed bona fide active enhancer features including P300 occupancy and high levels of H3K4me1 with low levels of H3K4me3. In addition, detailed analysis of epigenetic marks across 64 hematopoietic and non-hematopoietic cell lines and tissues revealed that his regulatory element is located within a major superenhancer specifically active in T-cells. Based on these results, we proposed that this regulatory sequence, hereby named N-Me for NOTCH-bound MYCenhancer, could function as an important regulatory element driving the activation of MYC downstream of NOTCH1 in T-ALL. Consistently, luciferase reporter assays showed strong, orientation-independent and NOTCH-dependent activation of reporter constructs containing N-Me in association with a -2.5 kb MYC proximal promoter in JURKAT T-ALL cells. Next and to formally test the functional relevance of this enhancer in T-cell development and transformation we generated and characterized N-Me knockout and conditional knockout mice. N-Me null animals were viable and showed a marked and selective reduction in thymus size and cellularity as their only developmental alteration. Detailed immunophenotypic analysis of N-Me knockout thymocytes demonstrated accumulation of double negative 3 (DN3) T cells and marked reductions in double positive and CD4+ and CD8+ single positive cells. Mechanistically, this phenotype was associated with a marked reduction in Myc expression in DN3, DN4 and ISP cells. Moreover, transplantation of N-Me knockout bone marrow hematopoietic progenitors demonstrated that this phenotype is cell autonomous, and can be rescued upon retroviral expression of MYC. Next, we analyzed the role of N-Me in the induction of NOTCH-driven leukemias by transplanting mice with N-Me wild-type and knockout hematopoietic progenitors infected with retroviruses expressing a mutant constitutively active form of NOTCH1 (ΔE-NOTCH1). In this context, mice transplanted with ΔE-NOTCH1-infected N-Me wild type cells developed T-ALL with 100% penetrance 6 weeks after transplant. In contrast, mice transplanted with ΔE-NOTCH1-N-Me knockout cells showed complete resistance to NOTCH1-induced transformation remaining 100% leukemia-free at 15 weeks post-transplant. In addition, secondary deletion of N-Me in established NOTCH1 induced leukemias from tamoxifen-inducible N-Me conditional knockout mice (Rosa26TMCre N-Meflox/flox) induced profound antileukemic effects with extended survival and almost complete suppression of leukemia initiating cell activity. Altogether, these results identify N-Me as the first long range oncogenic enhancer directly implicated in the pathogenesis of human leukemia. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

8

Quintás-Cardama, Alfonso, Hagop Kantarjian, and Jorge Cortes. "T Cell Blast Phase (T-BP) of Chronic Myelogenous Leuikemia (CML)." Blood 110, no. 11 (November 16, 2007): 4560. http://dx.doi.org/10.1182/blood.v110.11.4560.4560.

Full text

Abstract:

Abstract Approximately 65% of patients with CMP BP exhibit a myeloid phenotype, 30% a lymphoid, and 5% of cases have and undifferentiated or mixed phenotype. Most cases of lymphoid BP are of B-cell origin. Only anecdotal cases of T-BP have been reported. To evaluate the incidence and outcome of T-BP, we reviewed 410 patients with CML who underwent transformation to BP at M.D. Anderson Cancer Center between January 1999 and April 2007. Six cases (4 female) were diagnosed as having T-BP (incidence 1.5%). Three patients presented initially with T-BP whereas 3 other cases evolved to T-BP from chronic phase. The median time from diagnosis to transformation was 8 months (range, 0–72). The median age was 50 years (range, 24–66), median white blood cell count at presentation 20.5x109/L (range, 2.6–104), hemoglobin 11.2 g/dL (range, 10.6–13.6), platelet count 139x109/L (range, 20–295), peripheral blood blasts 6% (range, 0–100), and bone marrow blasts 20% (range, 2–88). All but 1 presented with extramedullary disease: 2 with lymphadenopathy, 2 with lymphadenopathy and mediastinal mass (including 1 also with pericardial tamponade), and 1 with splenomegaly, lymphadenopathy, and granulocytic sarcoma of the breast. Four patients had an immunophenotype consistent with byphenotypic T-cell/myeloid leukemia and 2 exhibited an exclusive T-cell phenotype. Three patients expressed a b2a2 BCR-ABL1 transcript (p210), whereas 1 carried b2a2+b3a2 (p210), 1 e1a2 (p190), and 1 expressed an e13b2+e14a2 (p210) transcript at the time of transformation but this switched to e1a2 (p190) during the course of dasatinib therapy. Three patients had failed prior therapies, including interferon-alpha (n=3), high dose imatinib (n=1), and matched-unrelated stem cell transplantation (SCT; n=1) at the time of transformation. Initial therapy for T-BP consisted of chemotherapy: hyper-CVAD in 3 patients (in 1 case with imatinib 600 mg daily), VAD in 1 patient, and a combination of idarubicin and ara-C in 2 cases (1 of them with imatinib 600 mg daily and dexamethasone). Only the 2 patients treated with chemotherapy and imatinib responded, achieving a complete cytogenetic response (CCyR) that lasted 3 and 14 months, respectively. Subsequent therapy in the remainder 4 patients consisted of high-dose imatinib (600–800 mg daily; n=4), which was administered for a median of 27 months (range, 0.5–87), dasatinib (n=1), autologous SCT (n=1), allogeneic SCT (n=1), and other chemotherapeutic regimens (n=4). One of the patients treated with imatinib (600 mg daily) achieved a complete molecular response (CMR) that is ongoing after 87 months of therapy. The patient treated with dasatinib (70 mg twice daily) achieved a CCyR. This patient presented the previously unreported K271R ABL kinase domain mutation prior to the start of dasatinib therapy. At the time of dasatinib failure, DNA expansion of specific clones followed by DNA sequencing detected the dasatinib-resistant mutations V299L and F317L in 80% and 20% of clones, respectively. Currently, 4 patients are dead while 2 are still alive, 1 in CMR receiving imatinib and 1 in CCyR after allogeneic SCT. In conclusion, T-BP is a rare variety of BP CML, which frequently exhibits extramedullary disease and high resistance to conventional chemotherapeutic regimens. Long-term responses can be achieved with ABL kinase inhibitors and/or allogeneic SCT.

APA, Harvard, Vancouver, ISO, and other styles

9

KATAEV, BORIS M., and JOACHIM SCHMIDT. "Brachypterous ground beetles of the Trichotichnus subgenus Bottchrus Jedlička (Coleoptera, Carabidae) from the Himalaya, with description of fifteen new species." Zootaxa 4323, no. 3 (September 22, 2017): 301. http://dx.doi.org/10.11646/zootaxa.4323.3.1.

Full text

Abstract:

The paper deals with the taxonomy of brachypterous species of the subgenus Bottchrus Jedlička, 1935 of the genus Trichotichnus Morawitz, 1863 occurring in the Himalayan region. The following new species are described: T. (B.) baglungensis sp. n. from the Baglung Lekh mountain range, Baglung District, western Central Nepal; T. (B.) parvulus sp. n. from Mt. Panchhase and the Krapa Danda mountain range, Kaski District, western Central Nepal; T. (B.) bubsaensis sp. n. from the eastern slope of the middle Dudh Koshi Valley near Bubsa, Solu Khumbu District, eastern Central Nepal; T. (B.) schawalleri sp. n. from the western slope of the Arun Valley, Bhojpur District, East Nepal; T. (B.) obliquebasalis sp. n. from the Khimti Khola Valley near Shivalaya, Dolakha District, eastern Central Nepal; T. (B.) panchhaseensis sp. n. from Mt. Panchhase, Kaski District, western Central Nepal; T. (B.) siklesensis sp. n. from the Sikles mountain range on the southern slope of Annapurna Peak II, western Central Nepal; T. (B.) pusillus sp. n. from the south-western slopes of Manaslu Himal (Bara Pokhari Lekh and Dudh Pokhari Lekh mountain ranges), and from the south-eastern slope of Annapurna Himal (Telbrung Danda mountain range), Lamjung District, western Central Nepal; T. (B.) ganeshensis sp. n. from the south-western slope of Ganesh Himal, Nuwakot District, Central Nepal; T. (B.) minutus sp. n. from the mountains surrounding the Kathmandu Valley (Shivapuri Lekh, Mt. Phulchoki), Central Nepal; T. (B.) gupchiensis sp. n. from the Gupchi Danda mountain range on the south-eastern slope of Manaslu Himal, Gorkha District, western Central Nepal; T. (B.) brancuccii sp. n. from the southern slope of the Helambu mountain range, Sindhupalchok District, Central Nepal; T. (B.) manasluensis sp. n. from the Bara Pokhari Lekh mountain range on the south-western slope of Manaslu Himal, Lamjung District, western Central Nepal; T. (B.) sikkimensis sp. n. from Pelling near Geyzing, West Sikkim, India; T. (B.) martensi sp. n. from the western slopes of the Singalila mountain range, Taplejung District, East Nepal. The following four species are redescribed: brachypterous T. (B.) holzschuhi Kirschenhofer, 1992; T. (B.) cyanescens Ito, 1998; T. (B.) hingstoni Andrewes, 1930; and dimorphic T. (B.) birmanicus Bates, 1892; and new data on their distribution are provided. The lectotype is designated for T. hingstoni Andrewes, 1930. The following two new synonyms are proposed: Trichotichnus birmanicus Bates, 1892 = T. (Bellogenus) probsti Kirschenhofer, 1992, syn. n., and T. hingstoni Andrewes, 1930 = T. (Pseudotrichotichnus) curvatus Ito, 1996, syn. n. The brachypterous and dimorphic species of Bottchrus known from the Himalaya are divided into eight informal groups based mostly on the degree of reduction of hindwings and the configuration of the median lobe of the aedeagus, and their relationships are briefly discussed. The distributional data of all these species are mapped.

APA, Harvard, Vancouver, ISO, and other styles

10

Farenick, D. R. "C*-Convexity and Matricial Ranges." Canadian Journal of Mathematics 44, no. 2 (April 1, 1992): 280–97. http://dx.doi.org/10.4153/cjm-1992-019-1.

Full text

Abstract:

AbstractC* -convex sets in matrix algebras are convex sets of matrices in which matrix-valued convex coefficients are admitted along with the usual scalar-valued convex coefficients. A Carathéodory-type theorem is developed for C*-convex hulls of compact sets of matrices, and applications of this theorem are given to the theory of matricial ranges. If T is an element in a unital C*-algebra , then for every n ∈ N, the n x n matricial range Wn(T) of T is a compact C* -convex set of n x n matrices. The basic relation W1(T) = conv σ-(T) is well known to hold if T exhibits the normal-like quality of having the spectral radius of β T + μ 1 coincide with the norm ||β T + μ 1|| for every pair of complex numbers β and μ. An extension of this relation to the matrix spaces is given by Theorem 2.6: Wn (T) is the C*-convex hull of the n x n matricial spectrum σn(T) of T if, for every B,M ∈ ℳn, the norm of T ⊗ B + 1 ⊗ M in ⊗ ℳn is the maximum value in {||∧⊗B + 1 ⊗M|| : Λ ∈ σn (T)}. The spatial matricial range of a Hilbert space operator is the analogue of the classical numerical range, although it can fail to be convex if n > 1. It is shown in § 3 that if T has a normal dilation N with σ (N) ⊂ σ (T), then the closure of the spatial matricial range of T is convex if and only if it is C*-convex.

APA, Harvard, Vancouver, ISO, and other styles

11

Abedin, Paniz, Arnab Ganguly, Solon P. Pissis, and Sharma V. Thankachan. "Efficient Data Structures for Range Shortest Unique Substring Queries." Algorithms 13, no. 11 (October 30, 2020): 276. http://dx.doi.org/10.3390/a13110276.

Full text

Abstract:

Let T[1,n] be a string of length n and T[i,j] be the substring of T starting at position i and ending at position j. A substring T[i,j] of T is a repeat if it occurs more than once in T; otherwise, it is a unique substring of T. Repeats and unique substrings are of great interest in computational biology and information retrieval. Given string T as input, the Shortest Unique Substring problem is to find a shortest substring of T that does not occur elsewhere in T. In this paper, we introduce the range variant of this problem, which we call the Range Shortest Unique Substring problem. The task is to construct a data structure over T answering the following type of online queries efficiently. Given a range [α,β], return a shortest substring T[i,j] of T with exactly one occurrence in [α,β]. We present an O(nlogn)-word data structure with O(logwn) query time, where w=Ω(logn) is the word size. Our construction is based on a non-trivial reduction allowing for us to apply a recently introduced optimal geometric data structure [Chan et al., ICALP 2018]. Additionally, we present an O(n)-word data structure with O(nlogϵn) query time, where ϵ>0 is an arbitrarily small constant. The latter data structure relies heavily on another geometric data structure [Nekrich and Navarro, SWAT 2012].

APA, Harvard, Vancouver, ISO, and other styles

12

LANGANKE, K., and C. ROLFS. "ON THE t(d, n)α REACTIVITY IN FUSION REACTORS." Modern Physics Letters A 04, no. 22 (October 30, 1989): 2101–12. http://dx.doi.org/10.1142/s0217732389002367.

Full text

Abstract:

We argue that the most accurate t(d, n)α cross section data obtained by the Los Alamos group are enhanced at energies smaller than Ecm≈16 keV due to screening effects caused by the electrons present in the target. We show that these data in the energy range Ecm=16–70 keV can be well reproduced by a single Breit-Wigner resonance formula which, however, disagrees with the data at lower energies. Consistently the observed deviations can be associated with electron screening effects where the latter are estimated within the Thomas-Fermi model or a static Hartree-Fock approach. Adopting the present Breit-Wigner fit to the data at Ecm≥16 keV , we have calculated the reactivity of a d+t plasma at thermal equilibrium in the temperature range kT<10 keV as it might be important for future fusion reactors.

APA, Harvard, Vancouver, ISO, and other styles

13

Li, C. B., and D. C. Mattis. "t–J Model with Infinite-Ranged Hopping." Modern Physics Letters B 11, no. 04 (February 10, 1997): 115–21. http://dx.doi.org/10.1142/s0217984997000165.

Full text

Abstract:

The complete spectrum of energy levels is found for the t–J model with infinite-range hopping (i.e. on a simplex of N sites), for arbitrary N. By comparison with free fermions on the same simplex, the two-body interactions break an important symmetry.

APA, Harvard, Vancouver, ISO, and other styles

14

Tan, Zhongquan, Enkelejd Hashorva, and Zuoxiang Peng. "Asymptotics of Maxima of Strongly Dependent Gaussian Processes." Journal of Applied Probability 49, no. 4 (December 2012): 1106–18. http://dx.doi.org/10.1239/jap/1354716660.

Full text

Abstract:

Let {Xn(t), t∈[0,∞)}, n∈ℕ, be standard stationary Gaussian processes. The limit distribution of t∈[0,T(n)]|Xn(t)| is established as rn(t), the correlation function of {Xn(t), t∈[0,∞)}, n∈ℕ, which satisfies the local and long-range strong dependence conditions, extending the results obtained in Seleznjev (1991).

APA, Harvard, Vancouver, ISO, and other styles

15

BELOUSOV, IGOR A., and ILYA I. KABAK. "New species of the genus Trechus Clairville, 1806 from the Chinese Tien Shan (Coleoptera: Carabidae)." Zootaxa 4679, no. 1 (October 1, 2019): 47–68. http://dx.doi.org/10.11646/zootaxa.4679.1.3.

Full text

Abstract:

Five new species of the genus Trechus Clairville, 1806 are described from the eastern part of the Tien Shan mountains (China, Xinjiang-Uygur Autonomous Region): T. tsanmensis sp. n. from the Narat Mountain Range, left bank of the Zanma River; T. torgaut sp. n. from the upper course of the Kunges River and Narat Mountain Range (both species belong to the uygur species group, which is defined here); T. aghiazicus sp. n. from the Aghiaz River and Koeksu Basin, T. cratocephalus sp. n. from the Narat Mountain Range (both belong to the micrangulus species group); and T. saluki sp. n. from the mountains S of the Kunges River (belonging to the kashensis species group, also defined in the present paper). Some new data on the distribution of T.uygur Deuve, 1993 and T. kashensis Belousov & Kabak, 2001 are given. The distribution of all known species of the uygur and kashensis groups is mapped. An identification key is provided to known species of the uygur group.

APA, Harvard, Vancouver, ISO, and other styles

16

Tan, Zhongquan, Enkelejd Hashorva, and Zuoxiang Peng. "Asymptotics of Maxima of Strongly Dependent Gaussian Processes." Journal of Applied Probability 49, no. 04 (December 2012): 1106–18. http://dx.doi.org/10.1017/s0021900200012900.

Full text

Abstract:

Let {Xn(t),t∈[0,∞)},n∈ℕ, be standard stationary Gaussian processes. The limit distribution oft∈[0,T(n)]|Xn(t)| is established asrn(t), the correlation function of {Xn(t),t∈[0,∞)},n∈ℕ, which satisfies the local and long-range strong dependence conditions, extending the results obtained in Seleznjev (1991).

APA, Harvard, Vancouver, ISO, and other styles

17

Smith, Keith, Gamal A. El-Hiti, Amany S. Hegazy, and Benson Kariuki. "A simple and convenient one-pot synthesis of substituted isoindolin-1-ones via lithiation, substitution and cyclization of N'-benzyl-N,N-dimethylureas." Beilstein Journal of Organic Chemistry 7 (September 6, 2011): 1219–27. http://dx.doi.org/10.3762/bjoc.7.142.

Full text

Abstract:

Lithiation of N'-benzyl-N,N-dimethylurea and its substituted derivatives with t-BuLi (3.3 equiv) in anhydrous THF at 0 °C followed by reaction with various electrophiles afforded a range of 3-substituted isoindolin-1-ones in high yields.

APA, Harvard, Vancouver, ISO, and other styles

18

Becker, V. O. "Five new species of the New World genus Thyridopyralis Dyar, 1901 (Lepidoptera: Pyralidae, Galleriinae)." SHILAP Revista de lepidopterología 50, no. 198 (June 30, 2022): 355–65. http://dx.doi.org/10.57065/shilap.147.

Full text

Abstract:

Five new species of Thyridopyralis Dyar, 1901 from Brazil are described, including diagnosis and illustrations: Thyridopyralis bonita Becker, sp. n., T. leucophthalma Becker, sp. n., T. minor Becker, sp. n., T. proxima Becker, sp. n. and T. viridescens Becker, sp. n.; the range of T. gallaerandialis Dyar, 1901 is extended to Mexico and the Antilles (Guana Id., British Virgin Islands).

APA, Harvard, Vancouver, ISO, and other styles

19

Marks, Peter W., and Frederick R. Maxfield. "Preparation of solutions with free calcium concentration in the nanomolar range using 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid." Analytical Biochemistry 193, no. 1 (February 1991): 61–71. http://dx.doi.org/10.1016/0003-2697(91)90044-t.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Bagno, Alessandro, Vlttorio Lucchini, and Glanfranco Scorrano. "Thermodynamics of protonation of N,N-dimethylthioamides in aqueous sulfuric acid." Canadian Journal of Chemistry 68, no. 10 (October 1, 1990): 1746–49. http://dx.doi.org/10.1139/v90-271.

Full text

Abstract:

The protonation (m* and [Formula: see text]) and thermodynamic (ΔG°, ΔH°, ΔS°) parameters of ionization of four thioamides RCSNMe2 (R = Me, Et, i-Pr, t-Bu) have been determined in aqueous sulfuric acid in the 25–60 °C temperature range with a UV technique. The title compounds are relatively strong bases; 100% protonation is reached in 47% H2SO4. Their solvation is lower than for primary thioamides and sulfides, as indicated by the higher values of m*, and close to the range of carbon bases. Base strengths are discussed in terms of the competition between internal and external stabilization. Keywords: basicity, protonation, solvation, thermodynamics, thioamides.

APA, Harvard, Vancouver, ISO, and other styles

21

Daley, D. J., T. Rolski, and Rein Vesilo. "Long-range dependent point processes and their Palm-Khinchin distributions." Advances in Applied Probability 32, no. 4 (December 2000): 1051–63. http://dx.doi.org/10.1017/s0001867800010454.

Full text

Abstract:

For a stationary long-range dependent point process N(.) with Palm distribution P0, the Hurst index H ≡ sup{h : lim sup t→∞t-2h var N(0,t] = ∞} is related to the moment index κ ≡ sup{k : E0(Tk) < ∞} of a generic stationary interval T between points (E0 denotes expectation with respect to P0) by 2H + κ ≥ 3, it being known that equality holds for a stationary renewal process. Thus, a stationary point process for which κ < 2 is necessarily long-range dependent with Hurst index greater than ½. An extended example of a Wold process shows that a stationary point process can be both long-range count dependent and long-range interval dependent and have finite mean square interval length, i.e., E0(T2) < ∞.

APA, Harvard, Vancouver, ISO, and other styles

22

Mattis, D. C. "Exact Eigenstates in Long-Ranged t–J Model." Modern Physics Letters B 11, no. 04 (February 10, 1997): 123–27. http://dx.doi.org/10.1142/s0217984997000177.

Full text

Abstract:

We present some exact eigenstates of the t–J model with infinite-range hopping (i.e. on a simplex of N sites) for arbitrary N, examine their degeneracy, obtain the low-temperature magnetic susceptibility, and observe a form of charge-spin separation.

APA, Harvard, Vancouver, ISO, and other styles

23

Yang, Junfang, Xian Zhang, Ying Liu, Xiao Yang, Hui Wang, Lin Wang, Jianqiang Li, and Peihua Lu. "High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)." Blood 138, Supplement 1 (November 5, 2021): 473. http://dx.doi.org/10.1182/blood-2021-147667.

Full text

Abstract:

Abstract Background Compared with the substantial efficacy of chimeric antigen receptor T-cell (CAR-T) therapy that has achieved in B-ALL, whether CAR-T therapy is effective and safe for patients with T-ALL is still being explored in early stage clinical trials. Here, we present outcomes from our phase 1 clinical trial of CD7-targeting CAR-T (CD7CAR) cells therapy for R/R T-ALL (NCT04572308). Methods Peripheral blood (PB) mononuclear cells were obtained by leukapheresis. T cells were separated and transduced with lentivirus. The second-generation CD7CAR is composed of an anti-CD7 single-chain antibody, a IgG4 hinge region, a CD28TM transmembrane domain, an intracellular co-stimulatory domain of 4-1BB and CD3ζ, and the truncated EGFR protein linked by T2A. All patients received intravenous fludarabine (30 mg/m 2/d) and cyclophosphamide (300 mg/m 2/d) for 3 days prior to CD7CAR infusion. Results Seventeen R/R T-ALL patients were enrolled between December 2020 and June 2021. Characteristics of patients are shown in Table 1. Data from 14 patients with a median age of 17 years (range: 3-42 years) were available for evaluation. The rest 3 patients were withdrawn from study within 14 days due to rapid disease progression. High-risk subtype patients enrolled including 1 with Ph-positive T-ALL and 3 with early T-cell precursor (ETP)-ALL. Seven of the 14 patients also had high-risk genotypes, namely SIL-TAL1, EZH2, TP53, RUNX1, BCR-ABL, JAK1 and JAK3. At enrollment, the median percentage of bone marrow (BM) blasts was 11.53% (range: 0.18%-65.03%), and 5 of 14 patients had extramedullary involvements, including optic nerve involvement (N=2), central nervous system leukemia (N=3), diffuse extramedullary involvements (N=2), and bulky lymph nodes in the neck (N=1). Patients were heavily pretreated with a median of 5 prior lines of therapies (range: 3-8 lines) and three relapsed from prior allogeneic hematopoietic stem cell transplantation (allo-HSCT). CD7CAR-T cells were 100% successfully manufactured with a transfection efficiency of 93.8% (range: 59.6%-99.9%). Twelve of 14 participants received bridging chemotherapy. A single dose of CD7CAR-T cells was infused to patients, with 2 receiving a low-dose (0.5x10 5 cells/kg), 11 receiving a medium dose (1-1.5x10 6 cells/kg) and 1 receiving a high-dose (2x10 6 cells/kg). By the data cutoff date (July 12, 2021), the median follow-up time was 105 days (range: 32-206 days, Fig.1A). By day 28 post infusion, 92.9% (13/14) of patients achieved complete remission (CR, N=4) or CR with incomplete hematological recovery (CRi, N=9) in their BM, with all 13 patients achieving minimal residual disease (MRD) negative CR/CRi. Additionally, 4/5 patients with extramedullary involvement also achieved extramedullary remission at a median of day 32 (range: 28-90 days) post infusion. Consolidation allo-HSCT was permitted at the treatment physician's discretion and the patient's preference. A total of 11/14 patients were bridged to consolidation allo-HSCT at a median of 57 days post CD7CAR infusion, of which 9 patients have remained MRD-negative CR/CRi. One patient who had allo-HSCT prior to CD7CAR infusion died following a second haplo-HSCT due to acute graft-versus-host disease. Of the other 3 patients who were not bridged to allo-HSCT, 1 patient relapsed on day 28 due to rapid disease progression after initial CRi on day 14. Thirteen of 14 patients experienced mild CRS (Grade ≤2). One patient had Grade 3 CRS. The median time to onset of CRS was 1 day (range: 0-11 days), with a median duration of 14 days (range: 3-25 days). Neurotoxicity (Grade 1) occurred in only 1 patient. After infusion, the median peak of CAR-T copy number was 2.38 ×10 5copies/µg DNA (range: 0.2-6.67 ×10 5 copies/µg DNA), which occurred on day 20 (range: 10-42 days, Fig.1B). Importantly, CD7CAR persisted well in PB at a median of 52.5 days (range:20-120 days) at last evaluation regardless of transplantation status. Maximum proportion of CD7CAR-T cells proliferation reached 84.95% by flow cytometry (Fig.1C). Conclusions Our results demonstrate that CD7CAR therapy is safe and highly effective in treating patients with heavily pretreated R/R T-ALL, including those with extramedullary involvements, a history of prior allo-HSCT or with high-risk subtypes. More patients and a longer observation time are needed to further evaluate the potential beneficial advantages and side effects of CD7CAR therapy for T-ALL patients. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

24

Searcóid, M. Ó., and T. T. West. "Continuity of the generalized kernel and range of semi-Fredholm operators." Mathematical Proceedings of the Cambridge Philosophical Society 105, no. 3 (May 1989): 513–22. http://dx.doi.org/10.1017/s0305004100077896.

Full text

Abstract:

Let X denote a Banach space over the complex field ℂ and let B(X) be the Banach algebra of all bounded linear operators on X. If T ε B(X), we write n(T) = dim ker (T) and d(T) = codim T(X). Suppose that Y is a subspace invariant under T; then TY will denote the restriction of T to Y and Y the operator on X/Y defined byY: x/Y →(Tx)/Y

APA, Harvard, Vancouver, ISO, and other styles

25

Sumachev, V. V., and Yu A. Beloglazov. "Multiplate polarimeter for neutrons in the energy range T n =200–800 MeV." Czechoslovak Journal of Physics 50, S1 (January 2000): 409–12. http://dx.doi.org/10.1007/s10582-000-0083-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kirpichenkova, Natalia V., Oleg I. Lozin, and Anastasia A. Kosach. "Numerical Modeling of the Anomalous Low-Temperature Dependence of the Tunneling Conductance of a "Dirty" N-I-N Junction." Solid State Phenomena 316 (April 2021): 1004–10. http://dx.doi.org/10.4028/www.scientific.net/ssp.316.1004.

Full text

Abstract:

A numerical study of the low-temperature tunneling conductance G(T) of the “dirty” (low concentrations of the same non-magnetic impurities in the I layer) N-I-N junction (N is a normal metal; I is an insulator) with random quantum jumpers penetrating the disordered I-layer is performed. In a wide range of low impurity concentrations, the dependence G(T) anomalously, both qualitatively and quantitatively, differs from the corresponding dependence G0(T) in the “pure” (without impurities in the I layer) N-I-N junction. The numerical analysis of the dependence G(T) shows the possibility of the experimental manifestation of these anomalies.

APA, Harvard, Vancouver, ISO, and other styles

27

Krishnan, Amrita Y., Joycelynne M. Palmer, Smita C. Bhatia, Auayporn Nademanee, Stephen J. Forman, Andrew Raubitschek, Arturo M. Molina, et al. "The Impact of Incorporating Targeted Radioimmunotherapy (RIT) into Transplant Preparative Regimens on the Incidence of Therapy Related Myelodysplasia (t-MDS) or AML (t-AML) Following Autologous Stem Cell Transplant (ASCT) for Lymphoma." Blood 110, no. 11 (November 16, 2007): 1082. http://dx.doi.org/10.1182/blood.v110.11.1082.1082.

Full text

Abstract:

Abstract The reported incidence of t-MDS/t-AML following traditional ASCT for lymphoma ranges between 0–12%. Previously identified risk factors include older age, prior alkylator therapy and use of radiation either prior to ASCT or as part of the preparative regimen. It is unclear whether novel conditioning regimens for ASCT that utilize targeted RIT with the potential to deliver higher radiation doses to the marrow are associated with a higher risk of t-MDS/t-AML. We identified a case-series of 83 pts who underwent RIT based ASCT between 06/00 and 01/06 to evaluate the incidence of t-MDS/t-AML; Forty-one pts received standard dose 90Y ibritumomab tiuxetan (0.4mci/kg: median dose 32.9 mci (range 20–40)) in combination with high dose BEAM (BCNU 450mg/m2, etoposide 800mg/m2, cytarabine 800mg/m2, melphalan 140mg/m2) and 42 pts received high dose 90Y based on dosimetry (median 70.8 mci range 36–105) in combination with etoposide 60mg/kg plus cyclophosphamide 100mg/kg. Pts were followed prospectively post ASCT with serial bone marrow biopsies approximately annually. The median age at ASCT was 54 years (range 19–78). Disease histology included diffuse large cell n=40, follicular NHL n=17, mantle cell n=21, transformed n=4, SLL n=1. Disease status at ASCT was 1st CR n=17, 1stPR n=14, induction failure n=14, 1st relapse or greater n=38. With a median follow-up of 39 months (range, 1.4–83), three patients (3.61%) have developed t-MDS/t-AML. The three pts also had associated complex chromosomal abnormalities including de1(13q), del(5q), del (20q). The median time to t-MDS/t-AML was 2.63 years (range, 1.51 – 8.41) post NHL diagnosis and 1.99 years (range, 0.56 – 5.10) post ASCT. The cumulative incidences of t-MDS/t-AML at 1 and 2 years were 1.20% (95%CI, 0.17– 8.1%) and 2.60% (95%CI 0.64–9.9%). None of the potential risk factors including age(>50 at ASCT) (p=0.33), prior radiotherapy (p=0.99), number of prior regimens (p=0.5) and 90Y dose (p=0.99) were statistically significant by univariate analysis. As 82/83 pts had received prior alkylator therapy this was not analyzed as a separate risk factor. Two year overall survival for the entire cohort is 90% (95%CI 83–95). Although the follow up is relatively short, the incidence of t-MDS/t-AML is consistent with our previous institutional experience in ASCT patients who received non-RIT based conditioning (Krishnan et al. Blood 2000) and with the 2.5% incidence of t-MDS/t-AML observed in pts receiving 90Y in registration and compassionate use trials (Czuczman et al JCO 2007 in press). In conclusion RIT based conditioning does not appear to confer an increased risk of t-MDS/t-AML above what has been previously reported with traditional ASCT preparative regimens. Incidence of t-MDS/t-AML Incidence of t-MDS/t-AML

APA, Harvard, Vancouver, ISO, and other styles

28

Tal, Pokalas P., M. S. Mahmud, M. A. Mbah, and R. U. Ndubuisi. "Maximum and Minimum Works Performed by T˜n." Modern Applied Science 16, no. 2 (April 22, 2022): 23. http://dx.doi.org/10.5539/mas.v16n2p23.

Full text

Abstract:

Let Xn and X*n be the finite sets {1,2,3,...,n} and {±1,±2,±3,..,±n} respectively. A map α: Xn→Xn is called a transformation on Xn We call α a signed transformation if α: Xn→X*n Let Tn and T&tilde;n be the sets of full and signed full transformations on Xn respectively. The work, w(α) performed by a transformation α is defined as the sum of all the distances |i-iα| for each i ϵ dom(α) In this paper, we present a range for the values of w(α) for all α ϵ Tn. Further, we characterize elements of T&tilde;n that attain minimum and maximum works and provide formulas for the values of these minimum and maximum.

APA, Harvard, Vancouver, ISO, and other styles

29

Papayannidis, Cristina, Ilaria Iacobucci, Mariachiara Abbenante, Annalisa Lonetti, Viviana Guadagnuolo, Anna Ferrari, Emanuela Ottaviani, et al. "Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience." Blood 118, no. 21 (November 18, 2011): 4250. http://dx.doi.org/10.1182/blood.v118.21.4250.4250.

Full text

Abstract:

Abstract Abstract 4250 Background. Nelarabine (N) is approved for the treatment of T-ALL and T-LBL that have not responded to or has relapsed after treatment with at least 2 chemotherapy regimens. Aim. To evaluate safety profile and efficacy of N as savage therapy in 16 adult relapsed or refractory T-ALL or T-LBL. Methods. After obtaining an informed consent, 16 patients (median age 33 years, range 19–45, M/F= 13/3) affected by T-ALL (n=10) and T-LBL (n=6) received savage therapy with N (median cycle=1, range 1–3), administered at standard adult dosage (1500 mg/sqm on days 1, 3 and 5, every 21). Four patients were primary resistant to induction treatment, 7 patients were relapsed after two previous chemotherapy regimens (including allogeneic BMT in 4 cases and autologous SCT in 1 case); the remaining 6 patients had a molecular relapsed disease (MRD positive). Molecular characterization was performed, including NOTCH and WT-1 genes mutational status. GEP analysis, according to Ferrando A. stratification (Cancer Cell 2002), is still ongoing. Results. Currently, 12 out of 16 patients are evaluable, due to a too short follow up in the other 4 cases. Seven out of 12 patients obtained a complete remission (CR) (5 T-ALL 2 T-LBL);a partial remission (PR) was documented in 2 cases, with an overall response rate (ORR) of 75%. Median duration of CR was 10 weeks (range 2.8–54+). Among these, 2 out of 4 patients in molecular relapse reached a molecular CR and underwent an allogenic BMT (currently in CR after a median follow up of 12 months). Extra- hematological toxicity, not clearly related to the drug, occurred in 3 cases, determining, a complete and irreversible paraplegia, a condition of mental confusion, and a peripheral neuropathy, respectively. Conclusions. N showed a strong efficacy also in cases with low levels of residual disease, in addition to a good safety profile. Neurological toxicity needs to be strictly monitored. Acknowledgments. European LeukemiaNet, AIL, AIRC, Fondazione Del Monte di Bologna e Ravenna, FIRB 2006, PRIN 2008, PRIN 2009, Ateneo RFO grants, Project of integrated program (PIO), Programma di Ricerca Regione – Università 2007 – 2009. Disclosures: Baccarani: Novartis: Consultancy, Honoraria; BMS: Consultancy, Honoraria. Martinelli:Pfizer: Consultancy; BMS: Consultancy, Honoraria; Novartis: Consultancy, Honoraria.

APA, Harvard, Vancouver, ISO, and other styles

30

Holmes, Randall R., Chi-Kwong Li, and Tin-Yau Tam. "Numerical Range of the Derivation of an Induced Operator." Journal of the Australian Mathematical Society 82, no. 3 (June 2007): 325–44. http://dx.doi.org/10.1017/s1446788700036156.

Full text

Abstract:

AbstractLet V be an n–dimensional inner product space over , let H be a subgroup of the symmetric group on {l,…, m}, and let x: H → be an irreducible character. Denote by (H) the symmetry class of tensors over V associated with H and x. Let K (T) ∈ End((H)) be the operator induced by T ∈ End(V), and let DK(T) be the derivation operator of T. The decomposable numerical range W*(DK(T)) of DK(T) is a subset of the classical numerical range W(DK(T)) of DK(T). It is shown that there is a closed star-shaped subset of complex numbers such that⊆ W*(DK(T)) ⊆ W(DK(T)) = con where conv denotes the convex hull of . In many cases, the set is convex, and thus the set inclusions are actually equalities. Some consequences of the results and related topics are discussed.

APA, Harvard, Vancouver, ISO, and other styles

31

Lindemann, Cécile, Pierre Duchet-Suchaux, Antonio Razzouk, Ilham Mokbel, and Jacques Jose. "Liquid–Liquid Equilibria of Binary and Ternary Systems Methanol/Water + n-Hexane, + n-Octane, + n-Dodecane, and + n-Hexadecane in the Temperature Range between T = 283.15 K and T = 333.15 K." Journal of Chemical & Engineering Data 61, no. 7 (June 7, 2016): 2412–18. http://dx.doi.org/10.1021/acs.jced.6b00022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Toumishey, Ethan, Angeli Prasad, Gregory S. Dueck, Neil Chua, Daygen Finch, Douglas A. Stewart, Darrell J. White, et al. "Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma." Blood 122, no. 21 (November 15, 2013): 4376. http://dx.doi.org/10.1182/blood.v122.21.4376.4376.

Full text

Abstract:

Abstract Background Patients with T-cell lymphomas face a poorer prognosis when compared to patients with B-cell lymphomas. New therapeutic approaches need to be developed in order to improve outcomes for these patients. We report the final results of a phase 2 multicenter clinical trial evaluating lenalidomide monotherapy in T-cell lymphomas. Methods Forty patients with relapsed and refractory T-cell lymphomas other than mycosis fungoides, as well as patients with untreated T-cell lymphoma who were not candidates for combination chemotherapy, were prescribed oral lenalidomide (25mg daily) on days 1 to 21 of each 28 day cycle, with standardized dose reductions for toxicity. Treatment continued until disease progression, death or unacceptable toxicity. The primary endpoint was overall response rate, and secondary endpoints were complete and partial response rates, progression-free and overall survival (PFS, OS), and safety. We also determined duration of response (DoR). Results Forty patients were enrolled in the study; one was subsequently deemed ineligible. In the 39 eligible patients, the median age was 65. ECOG PS was 0-1 (n=29), 2 (n=8), and 3 (n=2). The histology of the studied cases included peripheral T-cell unspecified (PTCL-u, n=14), angioimmunoblastic (n=9), anaplastic large cell (n=10), enteropathic T-cell (n=2), Hepatosplenic gamma/delta (n=2), and lymphoblastic T-cell lymphoma (n=2). The number of prior therapies was 0 (n=8), 1 (n=14), 2 (n=8), 3 (n=6), 4 (n=2), and 5 (n=1). Five patients had previous autologous stem cell transplant. Eleven patients were refractory to their previous treatment. The median time from diagnosis until the start of treatment was 14 months (range, 1-204 months). The median time from completion of prior therapy to the start of lenalidomide was 5 months (range, 1-48 months). The ORR was 10/39 (26%); 3 (8%) were complete responses and 7 were partial responses. Responses occurred in anaplastic, angioimmunoblastic, and PTCL-u histologies. Three additional patients had SD ≥5 cycles. The median OS was 12 months (range<1-69+ months), median PFS was 4 months (range,<1-50+ months) and the median DoR was 13 months (range 2-37+ months), including 5 responses lasting greater than 1 year. The most common grade 4 adverse event was thrombocytopenia (21%) while pain NOS (21%) and neutropenia (13%) were the most commonly reported grade 3 adverse events. Among the patients who had relapsed/refractory peripheral T-cell lymphoma (n=29) the ORR was 24%, median OS was 12 months, median PFS was 4 months, and median DoR was 5 months (range, 2-37+ months). The ORR of the subpopulation of previously untreated patients who were not eligible for combined chemotherapy (n=8) was 43%, median OS was 22 months (range,<1-38+ months), median PFS was 2 months (range,<1-38+ months), and median DoR was 21 months (range 5-28+ months). Discussion In T-cell lymphomas, oral lenalidomide monotherapy demonstrated clinically relevant efficacy. The toxicity profile in T-cell lymphoma is manageable and consistent with prior studies involving lenalidomide. Lenalidomide also showed promise for patients who are not eligible for combination chemotherapy. The results with lenalidomide in relapsed/refractory patients are comparable to those seen with other available monotherapies for this disease. Several durable (>1 year) responses were seen, but the proportion of durable responses was low. Future development of lenalidomide therapy for T-cell lymphomas should include efforts to identify the subset of patients most likely to benefit, and the development of rational drug combinations. Disclosures: Off Label Use: Lenalidomide was prescribed to treat T-cell lymphoma. Stewart:Celgene: Honoraria. van der Jagt:Millenium: Consultancy; Roche: Consultancy; Celgene: Consultancy. Reiman:Celgene: Consultancy; Celgene: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

33

Hann, Cynthia J., Alfred B. Sullivan, Brian C. Host, and George H. Kuhls. "Vulcanization Chemistry. Comparison of the New Accelerator N-t-Butyl-2-Benzothiazole Sulfenimide (TBSI) with N-t-Butyl-2-Benzothiazole Sulfenamide (TBBS)." Rubber Chemistry and Technology 67, no. 1 (March 1, 1994): 76–87. http://dx.doi.org/10.5254/1.3538668.

Full text

Abstract:

Abstract The sulfur vulcanization chemistry of cis-polyisoprene formulations accelerated with N-t-butyl-2-benzothiazole sulfenimide (TBSI) is compared to the chemistry of equivalent formulations accelerated with N-t-2-benzothiazole sulfenamide (TBBS). High performance liquid chromatographic analysis (HPLC) is utilized to examine the kinetics of accelerator-sulfur disappearance and the formation-appearance profiles of extra-network cure intermediates across the vulcanization process for stocks with a wide range of sulfur/accelerator ratios. Some unique features of TBSI vulcanization that distinguish it from TBBS are defined. A major distinction is the apparent consecutive step-wise kinetics of accelerator decay across the vulcanization process. A sequential reaction process may be indicated. Evidence is also offered that BtSxBt(x=2→6) is the crosslink precursor in TBSI vulcanization just as with TBBS formulations.

APA, Harvard, Vancouver, ISO, and other styles

34

Kröger, Helmut. "Contour integral representation of the on-shell T matrix." Canadian Journal of Physics 66, no. 9 (September 1, 1988): 791–95. http://dx.doi.org/10.1139/p88-129.

Full text

Abstract:

We suggest a contour integral representation for the on-shell T matrix in nonrelativistic N-body potential scattering with strong short range interactions. Results of a numerical calculation in the two-body system using a short range separable interaction of the Yamaguchi type are presented and show fast convergence towards the reference value.

APA, Harvard, Vancouver, ISO, and other styles

35

Maeda, Yasuhiro, Terufumi Yamaguchi, Chikara Hirase, and Akihisa Kanamaru. "Clinical Efficacy of ATRA for Adult T-Cell Leukemia." Blood 112, no. 11 (November 16, 2008): 4985. http://dx.doi.org/10.1182/blood.v112.11.4985.4985.

Full text

Abstract:

Abstract We previously reported that all-trans retinoic acid (ATRA) inhibited growth in HTLV-I- positive T-cell lines and fresh cells from patients with adult T-cell leukemia. We here confirmed the clinical effects of ATRA in 20 patients with ATL. Twenty patients (n=20) with median age of 56 years (range 35–68 years) diagnosed with ATL received ATRA orally. ATRA was administered for a median of 25.7 days (range 14–56 days). Efficacy was described below; no CR case, PR case was 55%, NR case was 45%. In 7 acute cases, PR case was 4 (20%) and NR case was 3 (15%). In 3 lymphoma cases, no NR case and 3 PR cases (15%) was found. In 4 chronic cases, PR case was 1 (4%) and NR case was 3 (15%). In 6 skin type. PR case was 3 (15 %) and NR case was 3 (15%). Major side effects were headache (n=5), transient liver dysfunction (n=2), hyperlipidemia (n=2) and anorexia (n=1). No major toxicity was observed. These results indicated that ATRA might be a useful agent for skin involvement of ATL with safety.

APA, Harvard, Vancouver, ISO, and other styles

36

Almeida, Jonatas C., Renata P. B. Melo, Pomy C. P. Kim, Neurisvan R. Guerra, Leucio C. Alves, Diego F. Costa, Clebert José Alves, Wagnner J. N. Porto, and Rinaldo A. Mota. "Molecular and serological investigation of infectious diseases in captive and free-range crab-eating fox (Cerdocyon thous – Linnaeus, 1776) from northeastern Brazil." Acta Parasitologica 63, no. 1 (March 26, 2018): 184–89. http://dx.doi.org/10.1515/ap-2018-0021.

Full text

Abstract:

Abstract The aim of this study was to detect DNA and antibodies anti-Leishmania spp., Neospora caninum and Toxoplasma gondii in captive and free-range crab-eating fox (Cerdocyon thous) from northeastern Brazil. Twenty-five crab-eating foxes from different states of northeastern Brazil were sampled by this study. Blood samples were collected by cephalic or jugular vein punctures. The whole blood was submitted to PCR, and the sera samples to the serological analysis as follows: MAT for T. gondii, NAT for N. caninum, and ELISA for L. chagasi. The frequence of antibodies anti-T. gondii was 50% and 29.41% for free-range and captive wild canids, respectively. The frequence of antibodies anti-N. caninum observed by this study was 62.50% and 23.52% for free-range and captive wild canids, respectively. The frequence of antibodies anti-L. chagasi was 4.0% for captive wild canids. Co-infections cases were identified as follows: one captive wild canid seropositive for T. gondii and L. chagasi and two free-range animals seropositive for T. gondii and N. caninum. All PCR assays performed were negative for the pathogens analyzed. This study describes the presence of antibodies anti-T. gondii, N. caninum e L. chagasi in wild canids from northeastern Brazil and highlights the necessity of further studies on infectious diseases in free-range and captive wild canids.

APA, Harvard, Vancouver, ISO, and other styles

37

Beltrán-Gárate, Brady E., Antonio A. Carrasco-Yalan, Olga M. Lopéz-Odría, Luis Riva-Gonzales, Hugo Ríos, Gloria Chumpitáz-Anchiraico, Silvia Falcón-Lisarazo, Juan Navarro-M, Fernando Hurtado de Mendoza, and Jorge Castillo-Aguirre. "Clinical Outcomes in Adult T Leukemia/Lymphoma: Report of 55 Cases from Peru." Blood 106, no. 11 (November 16, 2005): 4797. http://dx.doi.org/10.1182/blood.v106.11.4797.4797.

Full text

Abstract:

Abstract Adult T -cell leukaemia/lymphoma (ATL) is an aggressive disease associated with human T-cell lymphotropic virus type-I (HTLV-I) with heterogeneous clinical presentation and outcomes, described in Southern Japan, Europe, Caribbean and previously on Pacific coast of South America including Peru (EHA 2001, abst. 304). Shimoyama’s ATL classification (BHJ1991:79) includes four types: acute, lymphomatous, chronic and smoldering; recently a new clinical type cutaneous had been described (BJD2005:152). Herein we show our experience in ATL in our institution between October 1997 and May 2005 All our 55 cases shown positivity to HTLV-I Western Blot test; immune-histopathology, blood smears and flow cytometry showed mature T-cell lymphocyte. Median age at diagnosis 61 years old (range 23–84), female/male ratio: 1.2. Thirty-one (56%) patients had ECOG status performance at diagnosis ≥ 2. Clinical types: acute (n=26), lymphomatous (n=22), smouldering (n=2), cutaneous (n=5) with no chronic type observed. Median haemoglobin diagnosis was 12.1 g/dl (range 6.9–17), median albumin was 3.2 g/dl (range 1.8 – 4.9), median beta-2 microglobulin was 4.6 g/dl (range 1.5 – 16.9), median globulin was 2.7 g/dl (range 1.5 – 8.2) and DHL was 796 UI/ml (range 331 – 13000). Twenty-five per cent (9/36) debuted with hypercalemia (acute type=7, lymphomatous=2). Acute ATL showed median leukocytes of 48,900 cell/mm3 (range 6830–259,000). IPI risk score was: low (n=6), low intermediate (n=7), high intermediate (n=16) and high (n=27). Treatment for acute ATL was based on acute leukaemia and lymphoma regimens without any response but one, interestingly this patient was treated with Fludarabine 25 mg/mt2 day 1–5 each 28 day for 6 cycles and got complete remission. Twenty-one over 24 lymphomatous ATL type were evaluable for treatment response: overall response 38% (9/24) with 26% complete response. Smouldering and cutaneous ATL types received mainly topic treatments. Stratify analysis for IPI, DHL, beta-2 microglobulin, globulin and albumin for acute and non-acute ATL did not show any statistic difference. Median overall survival was: acute type (2.0 months DE 0.2), lymphomatous type (10.2 months DE 3.6), smouldering type (17.2 months) and cutaneous type (36.2 months DE 19.5) (Log Rank 30,76 p=0.0) ATL persist is a poor prognostic peripheral T-lymphocytic malignancy with bad clinical and therapeutically outcomes mainly in the acute type. Cutaneous type seems to be less aggressive. Figure Figure

APA, Harvard, Vancouver, ISO, and other styles

38

HUANG, HAO, PO-SHEN LOH, and BENNY SUDAKOV. "The Size of a Hypergraph and its Matching Number." Combinatorics, Probability and Computing 21, no. 3 (January 20, 2012): 442–50. http://dx.doi.org/10.1017/s096354831100068x.

Full text

Abstract:

More than forty years ago, Erdős conjectured that for any $t \leq \frac{n}{k}$, every k-uniform hypergraph on n vertices without t disjoint edges has at most max${\binom{kt-1}{k}, \binom{n}{k}-\binom{n-t+1}{k}\}$ edges. Although this appears to be a basic instance of the hypergraph Turán problem (with a t-edge matching as the excluded hypergraph), progress on this question has remained elusive. In this paper, we verify this conjecture for all $t < \frac{n}{3k^2}$. This improves upon the best previously known range $t = O\bigl(\frac{n}{k^3}\bigr)$, which dates back to the 1970s.

APA, Harvard, Vancouver, ISO, and other styles

39

Orza, J. A. G., R. Brito, T. P. C. van Noije, and M. H. Ernst. "Patterns and Long Range Correlations in Idealized Granular Flows." International Journal of Modern Physics C 08, no. 04 (August 1997): 953–65. http://dx.doi.org/10.1142/s0129183197000825.

Full text

Abstract:

An initially homogeneous freely evolving fluid of inelastic hard spheres develops inhomogeneities in the flow field u(r, t) (vortices) and in the density field n (r, t)(clusters), driven by unstable fluctuations, δa = {δn, δu}. Their spatial correlations, <δa(r, t)δa(r′,t)>, as measured in molecular dynamics simulations, exhibit long range correlations; the mean vortex diameter grows as [Formula: see text]; there occur transitions to macroscopic shearing states, etc. The Cahn–Hilliard theory of spinodal decomposition offers a qualitative understanding and quantitative estimates of the observed phenomena. When intrinsic length scales are of the order of the system size, effects of physical boundaries and periodic boundaries (finite size effects in simulations) are important.

APA, Harvard, Vancouver, ISO, and other styles

40

Leandro, De Padua Silva, Rima Saliba, Donna McCormick, Grace-Julia Okoroji, Amin Alousi, Paolo Anderlini, Stefan Ciurea, et al. "Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL)." Blood 114, no. 22 (November 20, 2009): 3213. http://dx.doi.org/10.1182/blood.v114.22.3213.3213.

Full text

Abstract:

Abstract Abstract 3213 Poster Board III-150 Background The use of anti-CD20 monoclonal antibody during stem cell collection has significantly improved transplant outcomes in b-cell NHL. The CD52 antigen is expressed on T-NHL, making it a suitable target for immunotherapy programs, given the availability of the anti-CD52 alemtuzumab. Methods In this prospective trial, alemtuzumab was given at 3,10, 30 mg IV (days 1-3) and then 30 mg IV, 7 days later. G-CSF (10mcg/kg) and GM-CSF 250 mcg/m2 were provided daily, 5 days after starting alemtuzumab, and until a target of at least 2×106 CD34+ cells/kg was collected. Patients (pts) then underwent conditioning with standard BEAM. Results Sixteen pts [Peripheral T-cell (n=6); angioimmunoblatic (n=2); anaplastic large cell (n=4); hepatoslenic (n=2); NK/T (n=2)] were enrolled. Pts were required to have adequate counts (platelets >100K, ANC >1.5). Median age was 44 (range, 22-62) years. Median prior treatments was 1 (range,1-7). At study entry (SE), 8 pts (50%) were in first remission, 7 (44%) had chemosensitive relapse, and one pt had chemorefractory disease. Median IPI at SE, was 0 (range 0-1) and median marrow cellularity was 40% (ranged, 10%-90%). Five of 15 pts tested (33%) had marrow involvement at any time, and 3 of 8 tested (37.5%) had evidence of clonal T-cell by PCR at the time of SE. Eight pts (50%) failed to mobilize an adequate number of stem cells; a rate that is comparable to our historical control with cytokine mobilization alone in b-cell malignancies with rituximab (Am J Hematol 2009;84:335). The median time to start apheresis in the pts who were able to mobilize successfully was 4.5 (range, 2-7) days after initiation of cytokine administration. The median number of CD34×106/Kg collected was 5.9 (range, 4-13.5). The median number of collection days was 4(range, 2-6). Three of the failures underwent successful mobilization with chemotherapy, and 2 underwent marrow harvest. There was a trend for a higher risk of failure in pts who had received more > one chemotherapy regimen, those who had been exposed to Hyper-CVAD (4 of 5 failed), and those with bone marrow cellularity < 30%. Age did not appear to have had an impact. Due to small numbers however, none of these associations reached statistical significance. Only one of the 8 pts who mobilized developed ANC< 1500 and platelets <20K. Seven of the 16 pts experienced CMV reactivation (ELISA test) and responded to foscarnet therapy. Twelve pts (75%) were able to proceed to autologous transplantation. With a median follow-up time of 22 (range 1-47) months, overall survival and progression-free survival rates were 79% and 45%, respectively. Conclusions The use alemtuzumab with cytokines is safe and feasible during autologous stem cell collection. In order to decrease the risk of stem cell mobilization failures, futures trials incorporating either chemotherapy or plerixafor with the alemtuzumab are warranted Disclosures Khouri: Bayer Pharmaceuticals: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

41

Arora, S. C., and J. K. Thukral. "Factorization ofk-quasihyponormal operators." International Journal of Mathematics and Mathematical Sciences 14, no. 3 (1991): 439–42. http://dx.doi.org/10.1155/s0161171291000583.

Full text

Abstract:

LetAbe the class of all operatorsTon a Hilbert spaceHsuch thatR(T*kT), the range space ofT*KT, is contained inR(T*k+1), for a positive integerk. It has been shown that ifT ϵ A, there exists a unique operatorCTonHsuch that(i) T*kT=T*k+1CT ;(ii) ‖CT‖2=inf{μ:μ≥0 and (T*kT)(T*kT)*≤μT*k+1T*k+1} ;(iii) N(CT)=N(T*kT) and(iv) R(CT)⫅R(T*k+1)¯The main objective of this paper is to characterizek-quasihyponormal; normal, and self-adjoint operatorsTinAin terms ofCT. Throughout the paper, unless stated otherwise,Hwill denote a complex Hilbert space andTan operator onH, i.e., a bounded linear transformation fromHintoHitself. For an operatorT, we writeR(T)andN(T)to denote the range space and the null space ofT.

APA, Harvard, Vancouver, ISO, and other styles

42

Bshaena, Ismail, and Ulrich Joger. "A new gecko from Libya: Tarentola neglecta lanzai n. ssp." Amphibia-Reptilia 34, no. 3 (2013): 353–62. http://dx.doi.org/10.1163/15685381-00002913.

Full text

Abstract:

New findings from two Central Libyan oases extend the distribution area of the Saharan gecko Tarentola neglecta considerably to the East. Scale counts falling outside the range of the two known subspecies show that the new specimens belong to a third subspecies which is described here under the name Tarentola neglecta lanzai. A molecular phylogeny with mitochondrial genes presents further evidence that T. neglecta is the sister species of the Egyptian T. mindiae, both of which constitute a monophyletic clade within the T. fascicularis-deserti group.

APA, Harvard, Vancouver, ISO, and other styles

43

Arkenau, H., M. Trumper, B. Sirohi, G. Chong, I. Chau, A. Wotherspoon, A. Norman, A. Horwich, E. Matutes, and D. C. Cunningham. "Gemcitabine, cisplatin and methylprednisolone (GEM-P) in patients with T-cell lymphoma: Results from The Royal Marsden Hospital." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 17507. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.17507.

Full text

Abstract:

17507 Background: There is a need for novel, effective therapies for T-cell non-Hodgkin’s lymphoma (NHL). The combination of gemcitabine, cisplatin and methylprednisolone (GEM-P) has shown activity in patients (pts) with relapsed Hodgkin’s disease and NHL (Chau I et al. Br J Haematol 2003, Baetz T et al. Ann Oncol 2003). We report a single institution retrospective analysis of GEM-P for pts with T-cell NHL. Methods: Sixteen pts with T-cell NHL treated at the Royal Marsden Hospital between June 2001 and March 2005 with GEM-P (gemcitabine 1 g/m2 D1, 8, 15; cisplatin 100 mg/m2 D15; methylprednisolone 1 g D1–5, repeated every 28D) were identified. Results: 16 pts (9 males and 7 females) were analysed. Histological subtypes were: angioimmunoblastic (n = 5), T-cell enteropathy (n = 2), NK/T cell nasal-type (n = 2), T-cell anaplastic (n = 3) and peripheral T-cell unspecified (n = 3). Median age was 55 years (range: 18–71 years), 69% had IPI-score ≥ 2 and 69% had stage III/IV disease. 15 /16 pts were pre-treated: median number of prior treatments: 1 (range: 0–4). At the start of GEM-P treatment pts presented with: primary refractory disease (n = 3), 1st relapse (n = 6), 1st relapse refractory (n = 3), 2nd relapse (n = 2) and 4th relapse (n = 1). Median time from diagnosis of T-cell NHL to start of GEM-P was 8.9 months(m) and median number of cycles given was 3 (range: 1–6). Of 16 evaluable patients, 3 pts (19 %) achieved complete remission (CR), 8 pts (50 %) achieved partial remission (PR), (ORR= 69%; CI-95% 41.4–89.0) and 5 pts (31%) progressed while on GEM-P. One pt received high dose chemotherapy (melphalan/etoposide) after CR to GEM-P. After a median follow up of 17.4m the mean progression free survival (PFS) was 9m (range 1.15–37.5). The median overall survival (OS) has not been reached and the survival probability at 1 year was 68.2% (95% CI: 40–85). The main grade 3/4 toxicities were myelosuppression (leucopenia 62%, neutropenia 62% and anaemia 12%) and required granulocyte colony stimulating factor (GCSF) in 3 pts with neutropenic sepsis and in 1 pt with neutropenia. Conclusion: GEM-P has encouraging efficacy with an acceptable toxicity profile in pts with previously treated T-cell NHL. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

44

Aftabuzzaman, Mohammad, Mohammad Monirul Islam, Nasiruddin, Farhana Rahman Rima, Mohammad Nazrul Islam, and Mohammad Azhar Ali. "Thermoacoustic Properties of Binary Liquid Mixtures of Sulfolane with Aniline, N,N-Dimethylaniline and N,N-Diethylaniline at Different Temperatures and Atmospheric Pressure." Asian Journal of Chemistry 33, no. 11 (2021): 2796–802. http://dx.doi.org/10.14233/ajchem.2021.23383.

Full text

Abstract:

Densities and sound velocities of the binary liquid mixtures of sulfolane + aniline, sulfolane + N,N-dimethylaniline, sulfolane + N,N-diethylaniline over the whole range of composition and their pure component were measured at temperatures (T = 303.15, 308.15, 313.15 K) and atmospheric pressure. A high precision vibrating-tube densitometer was used for the measurements. From the measured values, excess adiabatic compressibility (βs E), excess sound velocity (uE), excess internal pressure (Pi E) and deviation of surface tension (Δγ) were calculated for each of the systems. The excess properties and surface tension deviation were fitted to the Redlich-Kister equation. All these properties have been discussed in terms of molecular interactions.

APA, Harvard, Vancouver, ISO, and other styles

45

Carpio, K. J. E., and D. J. Daley. "Long-Range Dependence of Markov Chains in Discrete Time on Countable State Space." Journal of Applied Probability 44, no. 04 (December 2007): 1047–55. http://dx.doi.org/10.1017/s0021900200003727.

Full text

Abstract:

When {X n } is an irreducible, stationary, aperiodic Markov chain on the countable state space X = {i, j,…}, the study of long-range dependence of any square integrable functional {Y n } := {y X n } of the chain, for any real-valued function {y i : i ∈ X }, involves in an essential manner the functions Q ij n = ∑ r=1 n (p ij r − π j ), where p ij r = P{X r = j | X 0 = i} is the r-step transition probability for the chain and {π i : i ∈ X } = P{X n = i} is the stationary distribution for {X n }. The simplest functional arises when Y n is the indicator sequence for visits to some particular state i, I ni = I {X n =i} say, in which case limsup n→∞ n −1var(Y 1 + ∙ ∙ ∙ + Y n ) = limsup n→∞ n −1 var(N i (0, n]) = ∞ if and only if the generic return time random variable T ii for the chain to return to state i starting from i has infinite second moment (here, N i (0, n] denotes the number of visits of X r to state i in the time epochs {1,…,n}). This condition is equivalent to Q ji n → ∞ for one (and then every) state j, or to E(T jj 2) = ∞ for one (and then every) state j, and when it holds, (Q ij n / π j ) / (Q kk n / π k ) → 1 for n → ∞ for any triplet of states i, j k.

APA, Harvard, Vancouver, ISO, and other styles

46

Kelley, Robin Kate, Kent C. Shih, Fadi S. Braiteh, Drew W. Rasco, Antoine Hollebecque, Filippo de Braud, Anthony Goncalves, et al. "A phase IB, multicenter, open-label study to assess the safety, tolerability, and efficacy of the pleiotropic pathway modifier CC122 administered orally to patients with advanced HCC." Journal of Clinical Oncology 35, no. 4_suppl (February 1, 2017): 379. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.379.

Full text

Abstract:

379 Background: CC122 is a novel cereblon-modulating agent with multiple biologic activities including potent immunomodulatory and antiangiogenic effects. CC-122 binding to cereblon promotes ubiquitination and subsequent degradation of lymphoid transcription factors Ikaros and Aiolos resulting in activation of T cells. Methods: Following establishment of oral CC122 3 mg daily (QD) as the MTD in phase 1a (Blood 122:2905 2013), an expansion cohort of advanced Hepatocellular Carcinoma (HCC) subjects was enrolled. All subjects had progressed on or were intolerant to sorafenib. Efficacy was assessed per RECIST 1.1 criteria. Results: As of Jan. 13, 2016, 25 advanced HCC subjects were enrolled. The median age was 59.6 years, median Child-Pugh score was 5 (range 5-8) and all were ECOG 0-1. Viral status was HBV 28%, HCV 28%, HBV/HCV 12% and non-viral 32%. 52% had alpha-fetoprotein ≥ 200. CC122 was well tolerated. Two subjects discontinued due to AEs. Dose reductions occurred in 32% (n = 8). The most common ( ≥ 5%) grade 3/4 AEs were neutropenia, ALT elevation (each n = 4, 16%), AST elevation (n = 3, 12%), asthenia, ascites, anemia, hyperbilirubinemia, pneumonia, and rash (each n = 2, 8%). Drugrelated serious AEs included vomiting and rash. 19 subjects were evaluable for efficacy. ORR was 10.5% (n = 2 PR, 1 confirmed) and Disease Control Rate (CR+PR+SD > 7 weeks) was 36.8%. The duration of response was 108 and 125 days in the 2 PRs. The median PFS was 57 days (MinMax: 28334, 95% CI: 45-135). CC122 treatment resulted in a median increase from baseline in peripheral blood activated and memory cytotoxic T cells by 64% (range: 17-213%, n = 6) and 78% (range: 30-111%, n = 6 (p < 0.05), respectively, and activated helper T cells by 106% (range: 62-218%, n = 7 (p < 0.05). CC122-activated T cells from the blood increased IFNg (2.73 fold; range: 0.45-26.1, n = 13) and IL2 (9.5 fold; range: 0.85-24.3, n = 11) production when compared to baseline (both P < 0.05) upon ex-vivo stimulation. Conclusions: CC122 3 mg QD appears to be well tolerated and activates cytotoxic T cells in HCC patients. Combination studies with sorafenib or nivolumab are recommended and underway. Clinical trial information: NCT01421524.

APA, Harvard, Vancouver, ISO, and other styles

47

Łoś, Szymon, Kazimierz Paprocki, Mirosław Szybowicz, and Kazimierz Fabisiak. "The n–Si/p–CVD Diamond Heterojunction." Materials 13, no. 16 (August 10, 2020): 3530. http://dx.doi.org/10.3390/ma13163530.

Full text

Abstract:

Due to the possible applications, materials with a wide energy gap are becoming objects of interest for researchers and engineers. In this context, the polycrystalline diamond layers grown by CVD methods on silicon substrates seem to be a promising material for engineering sensing devices. The proper tuning of the deposition parameters allows us to develop the diamond layers with varying crystallinity and defect structure, as was shown by SEM and Raman spectroscopy investigations. The cathodoluminescence (CL) spectroscopy revealed defects located just in the middle of the energy gap of diamonds. The current–voltage–temperature, I−V−T characteristics performed in a broad temperature range of 77–500 K yielded useful information about the electrical conduction in this interesting material. The recorded I−V−T in the forward configuration of the n–Si/p–CVD diamond heterojunction indicated hopping trough defects as the primary mechanism limiting conduction properties. The Ohmic character of the carriers flux permitting throughout heterojunction is intensified by charges released from the depletion layer. The magnification amplitude depends on both the defect density and the probability that biasing voltage is higher than the potential barrier binding the charge. In the present work, a simple model is proposed that describes I−V−T characteristics in a wide range of voltage, even where the current saturation effect occurs.

APA, Harvard, Vancouver, ISO, and other styles

48

GARG, ASHIM, and ADRIAN RUSU. "AREA-EFFICIENT ORDER-PRESERVING PLANAR STRAIGHT-LINE DRAWINGS OF ORDERED TREES." International Journal of Computational Geometry & Applications 13, no. 06 (December 2003): 487–505. http://dx.doi.org/10.1142/s021819590300130x.

Full text

Abstract:

Ordered trees are generally drawn using order-preserving planar straight-line grid drawings. We investigate the area-requirements of such drawings and present several results. Let T be an ordered tree with n nodes. We show that: • T admits an order-preserving planar straight-line grid drawing with O(n log n) area. • If T is a binary tree, then T admits an order-preserving planar straight-line grid drawing with O(n log log n) area. • If T is a binary tree, then T admits an order-preserving upward planar straight-line grid drawing with optimalO(n log n) area. We also study the problem of drawing binary trees with user-specified aspect ratios. We show that an ordered binary tree T with n nodes admits an order-preserving planar straight-line grid drawing with area O(n log n), and any user-specified aspect ratio in the range [1,n/ log n]. All the drawings mentioned above can be constructed in O(n) time.

APA, Harvard, Vancouver, ISO, and other styles

49

Federmann, Birgit, Martin Bornhauser, Lambros Kordelas, Dietrich W. Beelen, Gernot Stuhler, Rainer Schwerdtfeger, Matthias Stelljes, et al. "Results of a Phase II Study of Haploidentical Hematopoietic Cell Transplantation (HHCT) in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Clinical Outcome and Immune Reconstitution." Blood 114, no. 22 (November 20, 2009): 1203. http://dx.doi.org/10.1182/blood.v114.22.1203.1203.

Full text

Abstract:

Abstract Abstract 1203 Poster Board I-225 HHCT using reduced intensity conditioning (RIC) and immunomagnetic CD3/CD19 graft depletion is of low toxicity and enables fast engraftment even with grafts of low CD34 content. Immune reconstitution may be improved compared to graft CD34 selection due to the cotransplantation of facilitating cells, CD34- progenitors, dendritic cells and natural killer (NK)-cells. A prospective multicenter phase II study of HHCT using CD3/CD19-depleted grafts after RIC with fludarabine (150-200 mg/m2), thiotepa (10 mg/kg), melphalan (120 mg/m2), OKT-3 (5 mg/day, day -5 to +14) was initiated. No post grafting immunosuppression was applied if the graft contained <5×104 CD3+ cells/kg. 60 adults with median age of 45 years (range, 19-61) have been enrolled from 2002 to 2009. Diagnoses were AML (n=37), ALL (n=8), NHL (n=6), myeloma (n=4), CML (n=3), CLL (n=1) and MDS (n=1). Patients were “high risk” because of refractory disease (n=6), cytogenetics (n=5), chemosensitive relapse (n=26) or relapse after prior HCT (allo=16, auto=6, both=1). At HHCT, 30 patients were in CR and 30 in PR. Grafts contained median of 6.8×106 (range, 3.5-22) CD34+ cells/kg, 4.0×104 (range, 0.9-44) CD3+ T cells/kg and 2.8×107 (range, 0.00-37.3) CD56+ cells/kg. Engraftment was rapid with median of 12 days to >500 granulocytes/μL (range, 9-50) and 11 days to >20.000 platelets/μL (range, 7-38). Incidence of grade II-IV acute GVHD and chronic GvHD (cGvHD) was 47% and 15%, respectively. Non-relapse-mortality on day 100 was 25% and 44% for the whole study period. Current overall survival (OS) is 18 of 60 patients (30%) with median follow-up of 525 days (range, 21-1542) of patients alive resulting in a Kaplan-Meier estimate 1-year OS of 41% and 2-year OS of 24%. Kaplan-Meier estimate 1-year OS was 40 % in AML, 38 % in ALL and 67% in NHL patients. No positive impact of KIR-mismatch on survival even in the subgroup of patients with AML was observed. Patients with cGVHD had a trend toward better survival with 56% vs. 39% (p=0.09). 14 patients died because of infections. Detailed immune reconstitution was analyzed in 24 patients. NK-cell engraftment was fast with median of 248 CD16+56+CD3- cells/μl (range, 1-886) on day 20. Increased natural cytotoxicity receptors (NKP30, NKP44, NKP46) and NKG2A, but decreased NKG2D and KIR-expression was observed on NK-cells in the first 3 months. T-cells regenerated delayed with median of 191 CD3+ cells/μl (range, 38-799) on day 100. A slow reconstitution of CD8+ and CD4+ T-cells with median of 66 CD8+ (range, 8-170) vs. 70 CD4+ cells/μl (range, 12-301) on day 100 and 157 (range, 32-379) vs. 181 cells/μl (range, 19-980) on day 400 was observed. The subset of memory T-cells regenerated faster compared to naïve T-cells with median of 25 CD4+45RA+ (range, 4-109) vs. 80 CD4+45RO+ cells/μl (range, 0 to 255) and 46 (range 7-191) vs. 164 cells/μl (range, 66-323) on days 80 and 250, respectively. T-cell repertoire was skewed with oligoclonal T-cell expansion to day 100 and normalization after day 200. B-cell reconstitution was slow with median of 8 (range, 0-407) CD19+20+ cells/μl on day 100. 6 of these 24 patients received donor-lymphocyte-infusions for relapse or mixed chimerism resulting in acceleration of immune recovery in T- and NK-cells. In conclusion, HHCT using RIC and CD3/CD19 depleted grafts is of low toxicity and allows fast engraftment even with low doses of CD34 cells. Overall survival seems promising in a high risk patient cohort. Recovery of NK cells occurs early and fast. KIR receptor expression remains low in the first 3 months. T- and B-cell reconstitution is delayed but seems faster compared to published data after CD34 selection. To evaluate the treatment protocol earlier during the course of disease a new study has just been initiated. Disclosures: Off Label Use: The use of Fludarabine, Thiotepa, Melphalan and OKT-3 in the conditioning is off-label-use.

APA, Harvard, Vancouver, ISO, and other styles

50

ROCHA, C. F. D., G. F. DUTRA, D. VRCIBRADIC, and V. A. MENEZES. "The terrestrial reptile fauna of the Abrolhos Archipelago: species list and ecological aspects." Brazilian Journal of Biology 62, no. 2 (May 2002): 285–91. http://dx.doi.org/10.1590/s1519-69842002000200013.

Full text

Abstract:

We have studied the terrestrial reptile fauna of the Abrolhos Archipelago (a group of five islands located ca. 70 km off the southern coast of the State of Bahia, Brazil) and analyze here some of its ecological aspects such as diet, thermal ecology, activity, and some reproductive parameters. Three lizards comprise the archipelago's terrestrial reptile fauna: Tropidurus torquatus (Tropiduridae), Mabuya agilis (Scincidae), and Hemidactylus mabouia (Gekkonidae). The first two are diurnal and the latter is crepuscular/nocturnal (initiating activity at ca. 17:30). The activity period of T. torquatus extended from 5:30 to 18:30 h. Mean field body temperatures of active T. torquatus, M. agilis, and H. mabouia were, respectively, 34.0 ± 3.7ºC (range 23.8-38.0ºC; N = 75), 34.5 ± 2.2ºC (range 30.8-37.0ºC; N = 6), and 26.3 ± 1.1ºC (range 24.8-28.0ºC; N = 8). The predominant prey items in the diet of T. torquatus were ants, coleopterans, and hemipterans. In the diet of M. agilis, coleopterans were the most frequent prey items. For H. mabouia, the most important dietary items were orthopterans. Clutch size of T. torquatus averaged 4.1 ± 1.1 (range 2-6; N = 15) and was significantly related to female size (R² = 0.618; p = 0.001; N = 15). Clutch size for H. mabouia was fixed (two) and mean litter size of the viviparous M. agilis was 3.3 ± 0.6 (range 3-4; N = 3). Tropidurus torquatus and H. mabouia deposit their eggs under rocks in the study area, with the former burying them but not the latter; in both species, more than one female often oviposit under the same rock.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Harts Range (N T )'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles